517 related articles for article (PubMed ID: 34733287)
1. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
2. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
3. Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.
Nava S; Lisini D; Frigerio S; Bersano A
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830221
[TBL] [Abstract][Full Text] [Related]
4. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
5. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
Li R; Zhang J; Gilbert SM; Conejo-Garcia J; Mulé JJ
Nat Rev Urol; 2021 Sep; 18(9):543-555. PubMed ID: 34183833
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
7. A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy.
Vo MC; Ahn SY; Chu TH; Uthaman S; Pillarisetti S; Uong TNT; Lakshmi TJ; Kim M; Song GY; Jung SH; Yang DH; Ahn JS; Kim HJ; Park IK; Lee JJ
Cell Mol Immunol; 2021 Jun; 18(6):1599-1601. PubMed ID: 33782574
[No Abstract] [Full Text] [Related]
8. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
9. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Galon J; Bruni D
Nat Rev Drug Discov; 2019 Mar; 18(3):197-218. PubMed ID: 30610226
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
12. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
13. Combination strategies to maximize the benefits of cancer immunotherapy.
Zhu S; Zhang T; Zheng L; Liu H; Song W; Liu D; Li Z; Pan CX
J Hematol Oncol; 2021 Sep; 14(1):156. PubMed ID: 34579759
[TBL] [Abstract][Full Text] [Related]
14. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
15. Type I interferon-mediated tumor immunity and its role in immunotherapy.
Yu R; Zhu B; Chen D
Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.
Dosset M; Joseph EL; Rivera Vargas T; Apetoh L
Cells; 2020 Jul; 9(7):. PubMed ID: 32707692
[TBL] [Abstract][Full Text] [Related]
18. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors.
Derer A; Frey B; Fietkau R; Gaipl US
Cancer Immunol Immunother; 2016 Jul; 65(7):779-86. PubMed ID: 26590829
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations.
Colton M; Cheadle EJ; Honeychurch J; Illidge TM
Radiat Oncol; 2020 Nov; 15(1):254. PubMed ID: 33148287
[TBL] [Abstract][Full Text] [Related]
20. Role of Local Radiation Therapy in Cancer Immunotherapy.
Demaria S; Golden EB; Formenti SC
JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
